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mortality rate of patients with BP is still high, ranging from
13% to 38%.1,2 Recently, we reported the effectiveness of
rituximab, a monoclonal anti-CD20 antibody, as first-line
therapy for pemphigus.3 Therefore, we have attempted to
measure the utility of rituximab as first-line therapy for BP.
From 2010 to 2012 we performed a retrospective case–
control study in a referral centre in Taiwan, including
patients with the generalized form of BP requiring systemic
treatment. Diagnosis of BP was based on typical clinical pre-
sentations, characteristic histopathological findings, and the
presence of autoantibodies on direct and/or indirect immu-
nofluorescence studies. In the first-line combination therapy
group (group R), the regimen included four weekly infu-
sions of 500 mg rituximab (MabTheraTM; Roche, Basel, Swit-
zerland), and corticosteroids, with a starting dose of
prednisolone of 05 mg kg1 daily (Table 1). The dose of
corticosteroids was tapered rapidly after disease was
controlled. Each dose lasted for 3–4 weeks, with a total
duration of < 6 months. As a comparison (group C), to
ensure the similarity of severity, we included patients from
the same period receiving a similar starting dose of predniso-
lone for at least 6 months (Table 1). We excluded those
with localized or mild disease, which could be controlled by
topical treatment or a short course of systemic treatment. All
patients were followed for 1 year or until death. In both
groups, the average age, BP Disease Area Index values,4
blood eosinophil counts and the presence of comorbidities
were similar (Table 2). More than 90% of patients in group
R achieved complete remission (CR), a status of no estab-
lished or new lesions for at least 2 months,4 which was
significantly higher than in group C (P = 002). Notably,
eight of the patients achieving CR in group R achieved CR
off therapy (CRoff). Of these eight patients, four maintained
CRoff during the follow-up period of > 2 years. The other
four experienced disease recurrence. Nevertheless, relapses in
these cases were mild and easily controlled. The mean dura-
tion of CRoff in these four patients was 27 weeks (range
22–35 weeks). The risk of infection was slightly lower in
group R than in group C (31% vs. 53%), but it was not sta-
tistically significant (P = 022). Urinary tract infection and
pneumonia were the leading infections in groups R and C,
respectively. The 1-year mortality rate of group R was much
lower than that of group C (15% vs. 37%), but it was not
significantly different (P = 018).
To date, only anecdotal reports have mentioned the use of rit-
uximab in BP.5,6 Our study is the first to use rituximab as a first-
line treatment in BP, and demonstrates a significantly better rate
of CR than conventional treatment. A recent review article
reports infection and mortality rates of around 20%, and sug-
gests that careful and close monitoring may be neccessary.7
These results are consistent with ours. Indeed, infections are the
most important cause of mortality in our study, as also reported
in another study.8 Nevertheless, our study provides a comparison
and shows that first-line combination therapy has similar or even
lower rates of infection and mortality than conventional treat-
ment. This might result from rapid tapering and withdrawing
systemic corticosteroids in group R (Table 2), as a lower dose of
systemic corticosteroids may reduce the rate of mortality.9
In conclusion, we demonstrate that first-line combination
therapy with rituximab and corticosteroids is effective and rel-
atively safe for moderate-to-severe BP. A large prospective
study is needed to confirm our observations.
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Congenital hemidysplasia with ichthyosiform
naevus and limb defects (CHILD) syndrome
without hemidysplasia
DOI: 10.1111/bjd.13636
DEAR EDITOR, Congenital hemidysplasia with ichthyosiform nae-
vus and limb defects (CHILD) syndrome is a rare X-linked
dominant disorder caused by mutations in NSDHL.1,2 This gene
encodes the enzyme 3b-hydroxylsterol dehydrogenase, which
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catalyses a step in the cholesterol biosynthetic pathway.1 Char-
acteristic signs present at birth or in the first weeks of life,
namely strikingly unilateral ichthyosiform skin lesions with a
sharp midline demarcation, and ipsilateral limb defects (ran-
ging from hypoplasia of the phalanges to absence of the entire
extremity).1,3 The face is usually spared. The central nervous
system, lungs, heart and kidneys can also be involved.2 We
report a case of CHILD syndrome without the characteristic
hemidysplasia.
A 7-year-old girl was referred to our department for evalua-
tion of areas of persistently inflamed and hyperkeratotic skin.
She was born at 35 weeks of gestation by caesarean section for
breech presentation, without gross limb defects. Her medical
history revealed a radiological diagnosis of spinal chondrodys-
plasia punctata with atlantoaxial subluxation and intermittent
spinal compression, bilateral hip subluxation, severe neurode-
velopmental delay, chronic lung disease requiring tracheostomy
and night-time ventilation, gastro-oesophageal reflux and gas-
trostomy feeding. Brain magnetic resonance imaging had
revealed general loss of white matter bulk but with no asymme-
try. The skin lesions had been present from birth, and persistent
symptoms were recurrent painful fissuring and pruritus. Cutane-
ous examination revealed inflammatory ichthyotic lesions along
the lines of Blaschko on both upper limbs (right more than left),
in the right groin, and diffusely on both cheeks. In addition,
there were areas of persistent nonscarring alopecia bilaterally on
the scalp, one circular and well circumscribed, and the other
more diffuse, with no evidence of trichotillomania. Dysmorphic
facial features included deep-set eyes and epicanthic folds.
Importantly, and compatible with previous reports,4 the
patient’s mother had similar but much milder linear hyperkera-
totic skin lesions affecting the right arm and hand, but was
otherwise unaffected (Fig. 1).
Skin biopsy of affected skin from the patient showed fea-
tures compatible with ichthyosiform dermatosis: acanthosis
and extension of rete pegs of the epidermis, marked paraker-
atotic scaling with loss of the granular layer, occasional clus-
ters of neutrophils, and perivascular and dermal
lymphohistiocytic infiltrates (Fig. 2), but without the char-
acteristic verruciform xanthoma of CHILD syndrome. Array
comparative genomic hybridization analysis of peripheral
blood leucocyte DNA was normal, excluding large copy
number changes (resolution 150 kb). Sanger sequencing
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Fig 1. (a–d) Clinical and radiological images.
Large erythematous xerotic plaques in a linear
distribution on both upper limbs, affecting
the right groin and thigh, and diffusely
bilaterally on the cheeks. (e, f) Small areas of
nonscarring alopecia bilaterally on the scalp.
(g) Linear area of erythema and
hyperkeratosis on the mother’s right hand.
(h) A lateral view of the spine showing
punctate calcifications in the vertebrae, typical
of chondrodysplasia punctata.
(a)
(b)
Fig 2. (a, b) Skin biopsy showing features compatible with
ichthyosiform dermatosis: acanthosis and extension of rete pegs of the
epidermis, marked parakeratotic scaling with loss of the granular layer,
occasional clusters of neutrophils, and perivascular and dermal
lymphohistiocytic infiltrates. No verrucous xanthoma was seen. (a)
Magnification 109; (b) magnification 409.
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revealed a novel germline heterozygous microdeletion
inducing a frameshift and premature stop codon at position
119 of a total translated length of 373 amino acids in NSDHL
(c.357_358del, p.Arg119Serfs*1d), predicted damaging in
silico. This mutation is compatible with the previously
reported disease-causing mutations in classical CHILD syn-
drome,1 and on the basis of current knowledge confirmed a
genetic diagnosis of CHILD syndrome in both the patient
and her mother. No other changes in the gene were identi-
fied. Previously reported mutations have principally been
heterozygous nonsense or missense point mutations, and
large heterozygous deletions have been described.3,5 This
novel microdeletion would be predicted to cause loss of
function by truncating the protein before the catalytic site of
the gene product.
Traditionally, management of skin lesions in CHILD syn-
drome has been difficult; however, Paller et al. recently
reported an innovative and highly successful topical therapy in
two patients – co-application of cholesterol 2% and lovastatin
2% – based on the role of NSDHL in cholesterol metabolism.6
These results have been replicated in three further reports of
patients using co-application of cholesterol 2% and simvastatin
2%,7 and has been successfully trialled in our patient, with
complete resolution of erythema and hyperkeratosis in the
treated groin area.
Two other conditions are interesting to consider in this atypi-
cal case (Table 1). Firstly, the recently described allelic disorder
CK syndrome (MIM #300831), caused by milder mutations in
NSDHL, is characterized by cortical malformations, typical facial
features, asthenic body habitus and no described cutaneous phe-
notype. Our patient does not exhibit typical features of this syn-
drome. Secondly, Conradi–Hunermann–Happle (CHH)
syndrome is an X-linked dominant disorder caused by muta-
tions in the emopamil-binding protein gene (EBP), which gov-
erns the next step in the cholesterol biosynthetic pathway after
NSDHL. The presence of chondroplasia punctata, intellectual dis-
ability and alopecia have all been described in CHH syndrome;
however, disproportionate skeletal growth, growth deficiency,
characteristic linear/whorled pigmentary lesions and cataracts
were lacking in our patient. Furthermore, the histological fea-
tures in this case support a diagnosis of CHILD syndrome and
exclude a diagnosis of CHH.
Table 1 Comparison of features of congenital hemidysplasia with ichthyosiform naevus and limb defects (CHILD) syndrome, Conradi–Hunermann
–Happle (CHH) syndrome, CK syndrome and our patient
Syndrome CHILD CHH CK Our patient
Genetics X-linked dominant disorder
caused by heterozygous loss of
function mutations in NSDHL
X-linked dominant
disorder caused by
mutations in EBP
X-linked recessive
disorder caused by
milder mutations in
NSDHL
Heterozygous microdeletion
inducing a frameshift and
premature stop codon in NSDHL
Cutaneous
phenotype
Unilateral ichthyosiform skin
lesions with sharp midline
demarcation
Ichthyosiform
erythroderma
None described Inflammatory linearichthyotic lesions
on both upper limbs, right groin
and diffusely bilaterally on cheeks
Psychotropic skin lesions
Linear or whorled
pigmentary lesions Areas of nonscarring alopecia
Striated
ichthyosiform
hyperkeratosis
Patchy cicatricial
alopecia
Histopathological
features
Verruciform xanthoma Hyperkeratosis and
acanthosis
– Acanthosis and extension of rete
pegsHyperkeratosis, parakeratosis
and acanthosis Calcium deposits
within the stratum
corneum
Marked parakeratotic scaling
with loss of the granular
layer
Inflammatory and lipid-laden
infiltrated within the dermal
papillae Focal pigmentation
of basal layer
Occasional clusters of neutrophils
Perivascular and dermal
lymphohistiocytic infiltrates
Associated defects Congenital hemidysplasia Chondrodysplasia
punctata
Cortical malformations Spinal chondrodysplasia punctata
Ipsilateral limb defects
Intellectual disability
Characteristic
craniofacial features
Bilateral hip subluxation
Visceral malformations
Short stature Asthenic body habitus
Severe neurodevelopmental delay
CNS anomalies
Cataracts Behaviour problems
Chronic lung disease
Gastro-oesophageal reflux
CNS, central nervous system.
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A clear bilateral presentation in CHILD syndrome has been
reported rarely before, once with characteristic skin lesions
affecting the body folds in a near-symmetrical distribution,
associated with a novel missense mutation in NSDHL,8,9 twice
with contralateral linear skin lesions,1 once with bilateral,
almost symmetrical, linear lesions on the extremities.10 Our
case confirms this bilateral cutaneous presentation, emphasizes
the significant inter- and intrafamilial variation, and extends
the noncutaneous phenotype of CHILD syndrome.
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Desmocollin-specific antibodies in a patient
with Hailey–Hailey disease
DOI: 10.1111/bjd.13661
DEAR EDITOR, Hailey–Hailey disease (HHD) is caused by
mutations in the ATP2C1 gene, encoding Ca2+/Mn2+ ATPase
protein 1 (hSPCA1) in the human secretory pathway. We
report a case of HHD in which we detected desmocollin
(Dsc)-specific antibodies, and discuss a possible mechanism
of production of keratinocyte cell-surface-specific autoanti-
bodies in HHD.
In 2010, a 74-year-old Japanese woman presented with
a 9-year history of a skin lesion on the left axilla, groin
and perineum. The lesion was exacerbated in summer.
Topical steroids were effective but the skin eruption
recurred. The patient’s father and son had similar skin
lesions in intertriginous regions. Physical examination
revealed oozing plaques on the left axilla (Fig. 1a). A le-
sional skin biopsy revealed suprabasal acantholysis in the
epidermis (Fig. 1b).
On receiving informed consent we extracted genomic DNA
from the patient’s peripheral blood, and amplified 28 exons
of ATP2C1 by polymerase chain reaction (PCR), as described
previously.1 Sequencing of the products of PCR revealed two
thymine insertions at the site of an adenine deletion at nucleo-
tide 1216 (Fig. 1c).
Simultaneously, we examined the patient’s serum for the
presence of autoantibodies against keratinocyte cell surfaces.
A direct immunofluorescence (IF) study of perilesional skin
was positive for IgG in a net-like pattern (Fig. 1d), but neg-
ative for IgA, IgM and C3 after pretreatment with 40% etha-
nol.2
An indirect IF study revealed cell-surface reactivity posi-
tive for IgG in monkey oesophagus, but not in normal
human skin (Fig. 1e). Immunoblotting of an extract of nor-
mal human epidermis was negative for IgG. Enzyme-linked
immunosorbent assays (ELISAs) for desmogleins 1 and 3
gave negative results.
Recently, we developed novel ELISAs for detection of IgG
antibodies against Dscs 1–3 using mammalian recombinant
proteins (D. Ueo, N. Ishii, T. Hamada, K. Teye, T. Hashimoto,
Y. Hatano & S. Fujiwara, submitted for publication). The
novel IgG ELISAs for Dscs were extremely specific, and none
of 35 normal control sera exceeded the cut-off values in any
of the Dsc ELISAs. The ELISAs were positive for antibodies
against Dsc1 [optical density (OD) 031, cut-off 020] and
Dsc2 (OD 018, cut-off 007), but negative for antibodies
against Dsc3 (OD 010, cut-off 012).
We made a diagnosis of HHD with Dsc-specific IgG anti-
bodies. Two years later, during wintertime remission, the
level of antibodies against Dsc2 was much reduced (OD
007), and ELISAs were negative for antibodies against Dsc1
(OD 017) and Dsc3 (OD 002). We also performed an
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